About Evrysdi Evrysdi is an SMN2-splicing modifier designed to increase functional SMN protein production. With the introduction of a new tablet formulation, Evrysdi now offers an alternative ...

Spinraza treatment does not lead to significant kidney dysfunction in SMA patients with types 1 and 2, a safety and efficacy ...

A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and ...

New research suggests that electrical spinal cord stimulation could improve muscle function for patients who have spinal ...

For columnist Alyssa Silva, advances in the development of SMA treatments have felt like glimmers of miracles.

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

Describe how imaging and the use of new therapies for geographic atrophy secondary to age-related macular degeneration can fit into the treatment paradigm. Summarize innovations in imaging that ...

The condition poses significant challenges in both diagnosis and treatment, as its early symptoms ... is primarily characterized by the progressive shrinkage (atrophy) of soft tissues, including skin, ...

The press release extensively emphasizes the treatment's impact on geographic atrophy (GA) while potentially downplaying any limitations or adverse effects revealed in the clinical studies ...

If you're one of the 13% of American adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly melts away, so too does muscle. And if you're not one for weights ...

What is SPINRAZA and its current approval status? SPINRAZA is an approved treatment for spinal muscular atrophy in over 71 countries, currently delivered at a dose of 12 mg. Disclaimer ...